U.S. Narcolepsy Therapeutics Market Size & Outlook
U.S. narcolepsy therapeutics market, 2018-2030 (US$M)
Related Markets
U.S. narcolepsy therapeutics market highlights
- The U.S. narcolepsy therapeutics market generated a revenue of USD 1,186.4 million in 2023 and is expected to reach USD 1,867.4 million by 2030.
- The U.S. market is expected to grow at a CAGR of 6.7% from 2024 to 2030.
- In terms of segment, narcolepsy with cataplexy was the largest revenue generating treatment in 2023.
- Narcolepsy without Cataplexy is the most lucrative treatment segment registering the fastest growth during the forecast period.
Narcolepsy therapeutics market data book summary
| Market revenue in 2023 | USD 1,186.4 million |
| Market revenue in 2030 | USD 1,867.4 million |
| Growth rate | 6.7% (CAGR from 2023 to 2030) |
| Largest segment | Narcolepsy with cataplexy |
| Fastest growing segment | Narcolepsy without Cataplexy |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Narcolepsy with Cataplexy, Narcolepsy without Cataplexy, Secondary Narcolepsy |
| Key market players worldwide | Teva Pharmaceutical Industries Ltd, Jazz Pharmaceuticals PLC, Harmony Biosciences Holdings Inc Ordinary Shares, Novartis AG ADR, Janssen Pharmaceuticals, Eli Lilly and Co |
Other key industry trends
- In terms of revenue, U.S. accounted for 33.7% of the global narcolepsy therapeutics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. narcolepsy therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 244.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Narcolepsy Therapeutics Market Scope
Narcolepsy Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. narcolepsy therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to narcolepsy therapeutics market will help companies and investors design strategic landscapes.
Narcolepsy with cataplexy was the largest segment with a revenue share of 54.15% in 2023. Horizon Databook has segmented the U.S. narcolepsy therapeutics market based on narcolepsy with cataplexy, narcolepsy without cataplexy, secondary narcolepsy covering the revenue growth of each sub-segment from 2018 to 2030.
- U.S. Narcolepsy Therapeutics Treatment Outlook (Revenue, USD Million, 2018-2030)
- Narcolepsy with Cataplexy
- Narcolepsy without Cataplexy
- Secondary Narcolepsy
- U.S. Narcolepsy Therapeutics Product Outlook (Revenue, USD Million, 2018-2030)
- Central Nervous System stimulants
- Sodium Oxybate
- Selective Serotonin Reuptake Inhibitor (SSRI)
- Tricyclic antidepressants
- Other Products
Reasons to subscribe to U.S. narcolepsy therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. narcolepsy therapeutics market databook
-
Our clientele includes a mix of narcolepsy therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. narcolepsy therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. narcolepsy therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. narcolepsy therapeutics market outlook size, by treatment, 2018-2030 (US$M)
U.S. Narcolepsy Therapeutics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
